Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | LGMN | Q99538 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30919728 | 0.89 | CHRM4 (0.45) | GPR119LGMNMAPT | |
| SCHEMBL5546525 | 0.87 | GPR119 (0.51) | GPR119LGMNMAPTHRH3ALDH1A1 | |
| SCHEMBL19297512 | 0.86 | GPR119 (0.50) | GPR119LGMNMAPTHRH3ALDH1A1 | |
| SCHEMBL28385329 | 0.84 | USP2 (0.60) | GPR119LGMNMAPTHRH3KDM4E | |
| SCHEMBL30200611 | 0.84 | GPR119 (0.54) | GPR119MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL16611364 | 0.84 | MAPT (0.66) | LGMNMAPTGFERCASP6ALDH1A1 | |
| SCHEMBL4511501 | 0.83 | DRD2 (0.48) | GPR119MAPTGFERKDM4EGAA | |
| SCHEMBL23104104 | 0.83 | LGMN (0.46) | GPR119LGMNMAPTHRH3KDM4E | |
| SCHEMBL22629176 | 0.82 | ALDH1A1 (0.53) | GPR119MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL23502124 | 0.81 | CHRM4 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12377106-B2 | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK | NURIX THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023076303-A1 | PIPERIDINYLPYRAZINE-CARBOXAMIDE COMPOUNDS FOR TREATING AND PREVENTING CANCER AND FOR DEGRADING BTK | NURIX THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-113412259-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2021-09-17 | — | — | CN | disclosed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| CN-1395578-A | Byrido [2,3-d] pyrimidine-2, 7-diamine kinase inhibitors | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377106-B2 | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK | BTK, SYK, LYN | GPR119 4002/4885LGMN 2387/4885MAPT 4659/4885 |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | GPR119 4589/4885LGMN 855/4885MAPT 2223/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | GPR119 4589/4885LGMN 855/4885MAPT 2223/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | GPR119 3705/4885LGMN 2105/4885MAPT 3790/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | GPR119 4665/4885LGMN 1148/4885MAPT 3097/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | GPR119 4614/4885LGMN 1208/4885MAPT 3055/4885 |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | GPR119 3689/4885LGMN 1394/4885MAPT 3164/4885 |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | GPR119 732/4885LGMN 4363/4885MAPT 4678/4885 |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | GPR119 3689/4885LGMN 1394/4885MAPT 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.